Antral follicle responsiveness to FSH, assessed by the follicular output rate (FORT), is altered in Hodgkin’s lymphoma when compared with breast cancer candidates for fertility preservation

Sonigo, Charlotte; Comtet, Marjorie; Duros, Solène; Sifer, C.; Sermondade, Nathalie; Grynberg, Michaël

doi:10.1007/s10815-017-1059-3

Cited by 14 publications

(4 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ovarian sensitivity to gonadotropins varies from a patient to another, and plays a decisive role in the response of the ovary to stimulation. Therefore, it is a key element in improving IVF success rate [40][41][42] . FORT, FOI, and FSI can serve as a quantitative and qualitative marker of ovarian response, as they can effectively reflect the dynamic nature of FD, in response to exogenous Gn [43][44][45][46] .…”

Section: Discussionmentioning

confidence: 99%

Metabolic signatures in human follicular fluid identify lysophosphatidylcholine as a predictor of follicular development

Yang

et al. 2022

Commun Biol

View full text Add to dashboard Cite

In order to investigate the metabolic characteristics of human follicular fluid (FF) and to reveal potential metabolic predictors of follicular development (FD) with clinical implications, we analyzed a total of 452 samples based on a two-stage study design. In the first stage, FF samples from both large follicles (LFs) and matched-small follicles (SFs) of 26 participants were analyzed with wide-spectrum targeted metabolomics. The metabolic signatures were described by multi-omics integration technology including metabolomic data and transcriptomic data. In the second stage, the potential biomarkers of FD were verified using enzyme-linked immunoassay with FF and blood serum from an independent 200 participants. We describe the FF metabolic signatures from ovarian follicles of different developmental stages. Lysophosphatidylcholine (LPC) can be used as a biomarker of FD and ovarian sensitivity, advancing the knowledge of metabolic regulation during FD and offering potential detection and therapeutic targets for follicle and oocyte health improvements in humans.

show abstract

Section: Discussionmentioning

confidence: 99%

Metabolic signatures in human follicular fluid identify lysophosphatidylcholine as a predictor of follicular development

Yang

et al. 2022

Commun Biol

View full text Add to dashboard Cite

show abstract

“…Whether the cancer status may alter the efficiency of FP procedures remains ill established . Some authors pointed out reduced oocyte yield and responsiveness of antral follicles to ovarian stimulation in case of lymphoma in comparison with breast cancer . However, few data are available about a potential impact of disease severity on the outcomes of FP procedures.…”

Section: Discussionmentioning

confidence: 99%

In vitro maturation is a viable option for urgent fertility preservation in young women with hematological conditions

Sonigo

Bajeux

Boubaya

et al. 2020

Hematological Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…When metaphase II oocyte cryopreservation is performed before 35 years of age and before cancer treatment, the cumulative live birth rate (CLBR) is only 9.1% (CI − 0.7 to 19) if 5 metaphase II oocytes are cryopreserved and 35.8% (CI 4.3–57.2) if 8 metaphase II oocytes are cryopreserved 9 . As illustrated by the case of lymphoma, the number of cryopreserved metaphase II oocytes is generally lower than that in cases of other malignant diseases 10 . In this case, delayed FP performed after chemotherapy treatment and remission could allow metaphase II oocyte banking to increase the probability of live birth after metaphase II oocyte thawing 11 .…”

Section: Introductionmentioning

confidence: 95%

Feasibility and efficiency of delayed ovarian stimulation and metaphase II oocyte banking for fertility preservation and childbearing desire after fertility-impairing treatment

Miquel,

Liotta,

Hours

et al. 2023

Sci Rep

View full text Add to dashboard Cite

The aim of our study was to evaluate the feasibility and efficiency of delayed ovarian stimulation and metaphase II oocyte banking for fertility preservation after fertility-impairing treatment regardless of the initial disease. We conducted a cohort study based on population of women < 40 years of age with diminished ovarian reserve caused by fertility-impairing treatment (n = 129). Three groups of women were compared according to the type of initial disease: hematological malignancies, solid tumors, and benign diseases. The primary endpoint was the number of metaphase II oocytes collected per woman. We studied the cumulative live-birth rate per cycle with fertilized metaphase II oocyte, for women who wanted to conceive. We studied 245 delayed controlled ovarian stimulation cycles in 129 women: 201 for fertility preservation and 44 for in vitro fertilization and fresh embryo transfers. The number of metaphase II oocytes collected per woman after banking was similar in the three groups, with a mean of 10.7 ± 4.6, 12.3 ± 9.1, and 10.1 ± 7.6 metaphase II oocytes (p = 0.46), respectively. In the subgroup of women who wanted to conceive, the cumulative live birth rate per woman was 38%, with 8 live births for these 21 women. After fertility-impairing treatment, practitioners should discuss a fertility preservation procedure for banking metaphase II oocytes.

show abstract

Antral follicle responsiveness to FSH, assessed by the follicular output rate (FORT), is altered in Hodgkin’s lymphoma when compared with breast cancer candidates for fertility preservation

Cited by 14 publications

References 33 publications

Metabolic signatures in human follicular fluid identify lysophosphatidylcholine as a predictor of follicular development

Metabolic signatures in human follicular fluid identify lysophosphatidylcholine as a predictor of follicular development

In vitro maturation is a viable option for urgent fertility preservation in young women with hematological conditions

Feasibility and efficiency of delayed ovarian stimulation and metaphase II oocyte banking for fertility preservation and childbearing desire after fertility-impairing treatment

Contact Info

Product

Resources

About